Rocket Pharmaceuticals

RCKT

Market cap $327M

Overview Fund Activity

3.03 USD

-0.22

6.77%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

3.09

+0.06

1.98%

1 day

-6.77%

5 days

-5.61%

1 month

0%

3 months

11.4%

6 months

-65.69%

Year to date

-76.18%

1 year

-86.1%

5 years

-87.78%

10 years

-94.71%

About: Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

Employees: 299

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

72% more repeat investments, than reductions

Existing positions increased: 81 | Existing positions reduced: 47

41% more call options, than puts

Call options by funds: $1.71M | Put options by funds: $1.22M

12.11% less ownership

Funds ownership: 101.05% [Q1] → 88.94% (-12.11%) [Q2]

17% less funds holding

Funds holding: 234 [Q1] → 195 (-39) [Q2]

48% less first-time investments, than exits

New positions opened: 41 | Existing positions closed: 79

50% less funds holding in top 10

Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]

68% less capital invested

Capital invested by funds: $722M [Q1] → $233M (-$489M) [Q2]

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$4

32% upside

Avg. target

$8

164% upside

High target

$11

263% upside

6 analyst ratings

5 positive

83%

1 neutral

17%

0 negative

0%

B of A Securities Jason Zemansky	$10	Buy Upgraded	20 Aug 2025
Chardan Capital Geulah Livshits	$11	Buy Maintained	20 Aug 2025
Cantor Fitzgerald Josh Schimmer	$8	Overweight Maintained	8 Aug 2025
Canaccord Genuity Whitney Ijem	$10	Buy Maintained	25 Jul 2025
B of A Securities Greg Harrison	$4	Neutral Downgraded	25 Jul 2025
UBS Colin Bristow	$5	Buy Maintained	17 Jun 2025

See Analyst Rankings

Financial journalist opinion

Based on 7 articles about RCKT published over the past 30 days

Rocket Pharmaceuticals, Inc. (RCKT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 9:15 AM EDT Company Participants Gaurav Shah - CEO & Director Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Presentation Michael Ulz Equity Analyst All right. Good morning, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference.

Rocket Pharmaceuticals, Inc. (RCKT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the 2025 Cantor Fitzgerald Global Healthcare Conference and the Morgan Stanley 23rd Annual Global Healthcare Conference in New York. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside chat and manag.

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Zacks Investment Research

RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study

Rocket Pharmaceuticals' shares soar as the FDA lifts its clinical hold on the pivotal Danon disease gene therapy study.

RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study

Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.

The past year has been a disappointing one for gene therapies.

Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.

FDA Lifts Rocket Pharmaceuticals Study Hold For Rare Disease Gene Therapy

Rocket Pharmaceuticals Inc. RCKT stock is trading higher on Wednesday after the U.S. Food and Drug Administration (FDA) lifted the clinical hold on its pivotal Phase 2 trial of RP-A501 for Danon disease.

FDA Lifts Rocket Pharmaceuticals Study Hold For Rare Disease Gene Therapy

US FDA lifts clinical hold on Rocket Pharmaceuticals' gene therapy trial

Rocket Pharmaceuticals said on Wednesday that the U.S. Food and Drug Administration has lifted the clinical hold on its gene therapy mid-stage trial.

US FDA lifts clinical hold on Rocket Pharmaceuticals' gene therapy trial

Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company's pivotal Phase 2 trial of RP-A501 for the treatment of Danon disease. The hold was lifted in under three months, underscoring the efficiency of the FDA's review pr.

Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease

Levi & Korsinsky Reminds Rocket Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025 – RCKT

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit.

Levi & Korsinsky Reminds Rocket Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025 – RCKT

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

NEW YORK--(BUSINESS WIRE)---- $RCKT #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT) and reminds investors of the August 11, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT

NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT

See News Rankings

Charts implemented using Lightweight Charts™